Gilteritinib and the risk of intracranial hemorrhage: a case series of a possible, under-reported side effect

Gilteritinib is currently approved for patients with relapsed/refractory AML with FLT3 mutations, based on the positive results of the pivotal ADMIRAL study. In ADMIRAL trial, no increased risk of bleeding was reported, but in the previous dose finding study, a single event of intracranial hemorrhag...

Descripción completa

Detalles Bibliográficos
Autores principales: Perrone, Salvatore, Imperatore, Stefano, Sucato, Giuseppe, Notarianni, Ermanno, Corbingi, Andrea, Andriola, Costanza, Napolitano, Mariasanta, Pulsoni, Alessandro, Molica, Matteo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10567884/
https://www.ncbi.nlm.nih.gov/pubmed/37606693
http://dx.doi.org/10.1007/s00277-023-05392-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10567884/
https://www.ncbi.nlm.nih.gov/pubmed/37606693
http://dx.doi.org/10.1007/s00277-023-05392-2

Ejemplares similares